UPDATED

This just in after I posted the prior information:

Four years ago, scientists at the Illawarra Health and Medical Research Institute found out exactly why drugs like Zyprexa cause weight gain: it has an effect on the histaminergic system which regulates appetite.

Associate Professor Chao Deng and his team tested a drug called betahistine, used mostly for vestibular disorders like vertigo and dizziness, and found that when taken with olazapinem there's a great decrease in appetite.

According to Chao Deng, not only do the atypicals stimulate appetite: they change the way the body metabolizes food.

The team is interested in getting drug companies to do research on using betahistine to improve further treatment.

(Breathrough to reduce antipsychotic drug-induced obesity, retrieved on 7/16/12 from http://www.abc.net.au/local/stories/. . .)

Now the original news:

An Eli Lily schizophrenia drug expected to replace their drug Zyprexa that causes monster weight gain has bombed out in its late-stage clinical trial.  The experimental SZ drug known as mGlu2/3 simply did not work to treat the symptoms of this illness.  It is also known as pomaglumetad methionil.  Eli Lily awaits the results of a mid-stage study examining the drug as a combination treatment with existing atypical antipsychotics.

(Eli Lily schizophrenia drug fails late-stage trial, Reuters, retrieved on July 15, 2012 from http://www.reuters.com/article. . .)

NuPathe Inc. has been issued a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for a rod-shaped implant that would deliver therapeutic levels of risperidone for 20 to 190 days as well as for treating medication noncompliance in illnesses like schizophrenia and bipolar. 

The currently available depot injections or long-acting injectable versions of the drugs (LAIs) are effective only for two weeks or one month.  The three-month drug therapy could hold promise for ease of use for individuals who discontinue their medication repeatedly.

(NuPathe Announces Allowance of Additional U.s. Patent Application for NP202, retrieved on July 15, 2012 from http://www.marketwatch.com/story. . .)

In other news: The results of a study published online in the Archives of General Psychiatry reveal a higher risk of autism spectrum disorders (ASDs) in children whose parents or siblings have schizophrenia or bipolar.  Medical geneticists from North Carolina's School of Medicine University conducted a case-control study with data obtained from population registers in Sweden and Israel.

In Stockholm and the entire country of Sweden, the risk of ASD was nearly three times higher in those whose parents suffered from schizophrenia.  Those whose siblings had schizophrenia had a 2.5-times higher risk of autism in Sweden and a 12-times higher risk in a sample of Israeli military personnel.